Latest News
Weekly News Roundup | 17 August 2026
Life science news 17 August 2026: Donald Trump signs an executive order seeking to narrow the US childhood vaccine schedule, the MHRA makes the UK the first country in Europe to authorise Eli Lilly’s orforglipron tablet, and Jazz Pharmaceuticals pays $820 million...
Latest News
Weekly News Roundup | 29 June 2026
Life science news 29 June 2026: AbbVie and Merck KGaA announce blockbuster acquisitions totalling more than $22 billion, NICE recommends the first disease-modifying therapy for type 1 diabetes for NHS use, and Definium Therapeutics delivers a landmark Phase 3 result...
Why I Founded Mesogen: A New Vision for Personalized Regenerative Medicine
For much of my career I have been fascinated by a simple but profound question: What if medicine could restore what disease destroys? Modern medicine has achieved remarkable success in helping patients manage chronic illnesses. We have developed sophisticated drugs,...
Light-Driven Immune Modulation and Its Impact on Autoimmune Therapy
One of the most consistent epidemiological patterns in multiple sclerosis (MS) is its geographic distribution. Rates rise with distance from the equator, where year-round sunlight exposure is lower.[1] For decades, this has pointed to a role for environmental light in...
Merck KGaA Acquires Bio-Techne for $11.3 Billion in Life Science Tools Deal
The Merck KGaA Bio-Techne acquisition values the Minneapolis-based life science tools company at approximately $11.3 billion. Merck KGaA, the German science and technology group, announced on 25 June 2026 that it will acquire Minneapolis-based Bio-Techne Corporation...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Pharvaris Announces Positive Phase 3 Results for Deucrictibant
Pharvaris Announces Positive Phase 3 Results for Deucrictibant as On Demand HAE Treatment Pharvaris has announced positive topline data from its global Phase 3 RAPIDe 3 study, confirming that the oral bradykinin B2 receptor antagonist deucrictibant shows strong...
AI & Cloud Enabled R&D and Clinical Operations Surge in Life Sciences
Digital transformation is accelerating across the life sciences sector as more organisations adopt AI driven platforms and cloud computing to speed up drug discovery, streamline clinical trials and optimise operations. A recent industry overview from BioSpace...
Autolus CAR-T Offers Hope to Adults with Aggressive Blood Cancer
The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending a novel, next-generation chimeric antigen receptor T-cell (CAR-T) therapy for use in the National Health Service (NHS). This landmark decision is set to...
Otsuka Wins Approval for Novel Rare Kidney Drug
Otsuka Gains Approval for First of Its Kind Treatment Against Rare Kidney Disease In a significant milestone for kidney disease care, Otsuka Pharmaceutical has received accelerated approval from the US Food and Drug Administration for a new therapy for Immunoglobulin...
US and UK Agree Zero Tariffs Deal on Pharmaceuticals
US and UK Agree Zero Tariffs Deal on Pharmaceuticals: What It Means for Patients, Innovation and Global Pharma Trade The United States and the United Kingdom have reached a landmark trade agreement that eliminates tariffs on UK-origin pharmaceuticals, active...
Hot Topic to Watch in China Life Sciences: Data Exclusivity & IP Reforms
China’s life sciences sector is poised for a potential regulatory shake-up this week, as stakeholders await clarity on data exclusivity and intellectual property (IP) protection reforms. Earlier this year, the National Medical Products Administration (NMPA) released a...
A Milestone in Rare Disease Genomics
Why popEVE Matters Interpreting missense variants has long been one of the most persistent challenges in clinical genetics. These single–amino-acid substitutions can subtly alter protein structure or function, yet their effects are often context-dependent and...
Brain Cell Communication at the Molecular Level
Brain Cell Communication at the Molecular Level Neural communication isn’t abstract, it’s a sequence of tightly regulated biophysical events. Ion gradients shift, channels open and close with millisecond precision, calcium signals trigger chemical release, and...
Welcome to Life Science Daily News
Your Gateway to Discovery, Innovation, and Global Scientific Voices In a world where breakthroughs happen every day and scientific understanding is accelerating faster than ever before, Life Science Daily News stands as a vibrant hub for curious minds, passionate...
New Hope for Patients with Hereditary Hemorrhagic Telangiectasia
Engasertib Trial Offers New Hope for Patients with Hereditary Hemorrhagic Telangiectasia A recent clinical study has delivered encouraging results for people living with hereditary hemorrhagic telangiectasia, a rare genetic vascular disorder that causes chronic and...
ALS- Clinical Signals of a “Synaptic Regenerative” Approach!
Pharmaceutical approaches to ALS remain sparse and "hard-to-develop". Riluzole (approved 1995) and edaravone (IV in 2017, oral in 2022) only offer modest benefits. More recently, Biogen's Qalsody (tofersen) was approved for SOD1-mutant ALS. But a new wave of new...
Decision Frameworks in Pharma
Decision Frameworks in Pharma: From RAVE and DICE to Lilly’s Truth-Seeking Machine What Works, What Kills What, and Why It Matters In pharmaceutical R&D, where billions ride on the flip of a biological coin, decision frameworks aren’t just nice-to-haves - they’re...
Pharvaris Announces Positive Phase 3 Results for Deucrictibant
Pharvaris Announces Positive Phase 3 Results for Deucrictibant as On Demand HAE Treatment Pharvaris has announced positive topline data from its global Phase 3 RAPIDe 3 study, confirming that the oral bradykinin B2 receptor antagonist deucrictibant shows strong...
AI & Cloud Enabled R&D and Clinical Operations Surge in Life Sciences
Digital transformation is accelerating across the life sciences sector as more organisations adopt AI driven platforms and cloud computing to speed up drug discovery, streamline clinical trials and optimise operations. A recent industry overview from BioSpace...
Autolus CAR-T Offers Hope to Adults with Aggressive Blood Cancer
The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending a novel, next-generation chimeric antigen receptor T-cell (CAR-T) therapy for use in the National Health Service (NHS). This landmark decision is set to...
Otsuka Wins Approval for Novel Rare Kidney Drug
Otsuka Gains Approval for First of Its Kind Treatment Against Rare Kidney Disease In a significant milestone for kidney disease care, Otsuka Pharmaceutical has received accelerated approval from the US Food and Drug Administration for a new therapy for Immunoglobulin...
US and UK Agree Zero Tariffs Deal on Pharmaceuticals
US and UK Agree Zero Tariffs Deal on Pharmaceuticals: What It Means for Patients, Innovation and Global Pharma Trade The United States and the United Kingdom have reached a landmark trade agreement that eliminates tariffs on UK-origin pharmaceuticals, active...
Hot Topic to Watch in China Life Sciences: Data Exclusivity & IP Reforms
China’s life sciences sector is poised for a potential regulatory shake-up this week, as stakeholders await clarity on data exclusivity and intellectual property (IP) protection reforms. Earlier this year, the National Medical Products Administration (NMPA) released a...
A Milestone in Rare Disease Genomics
Why popEVE Matters Interpreting missense variants has long been one of the most persistent challenges in clinical genetics. These single–amino-acid substitutions can subtly alter protein structure or function, yet their effects are often context-dependent and...
Brain Cell Communication at the Molecular Level
Brain Cell Communication at the Molecular Level Neural communication isn’t abstract, it’s a sequence of tightly regulated biophysical events. Ion gradients shift, channels open and close with millisecond precision, calcium signals trigger chemical release, and...
Welcome to Life Science Daily News
Your Gateway to Discovery, Innovation, and Global Scientific Voices In a world where breakthroughs happen every day and scientific understanding is accelerating faster than ever before, Life Science Daily News stands as a vibrant hub for curious minds, passionate...
New Hope for Patients with Hereditary Hemorrhagic Telangiectasia
Engasertib Trial Offers New Hope for Patients with Hereditary Hemorrhagic Telangiectasia A recent clinical study has delivered encouraging results for people living with hereditary hemorrhagic telangiectasia, a rare genetic vascular disorder that causes chronic and...
ALS- Clinical Signals of a “Synaptic Regenerative” Approach!
Pharmaceutical approaches to ALS remain sparse and "hard-to-develop". Riluzole (approved 1995) and edaravone (IV in 2017, oral in 2022) only offer modest benefits. More recently, Biogen's Qalsody (tofersen) was approved for SOD1-mutant ALS. But a new wave of new...
Decision Frameworks in Pharma
Decision Frameworks in Pharma: From RAVE and DICE to Lilly’s Truth-Seeking Machine What Works, What Kills What, and Why It Matters In pharmaceutical R&D, where billions ride on the flip of a biological coin, decision frameworks aren’t just nice-to-haves - they’re...
Featured Articles
Further News
Follow the Science? It Would Rather Follow a Leader… (2025 Update)
Eight years on from the first version of this article, “follow the science” is still the industry’s favourite comfort blanket. It sounds noble, unassailable, the kind of thing you put on a lab-wall poster next to a photo of Rosalind Franklin. (Following the X...
Durvalumab approved in the US
Durvalumab approved in the US as first & only perioperative immunotherapy for patients with early gastric & gastroesophageal cancers! The FDA approved Durvalumab (Imfinzi) in combination with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)...
Redefining Drug Safety: Global Regulators Push for AI and 3D Tissues
For decades, the laboratory rat has been the quintessential symbol of biomedical research. Yet, as 2025 draws to a close, a profound shift is reshaping the life sciences landscape. Global regulatory bodies are no longer merely encouraging alternatives to animal...
Novartis to Acquire Avidity in $12B RNA Therapy Deal
The biotech M&A boom shows no signs of slowing. Novartis has struck a definitive agreement to acquire Avidity Biosciences for US$12 billion in cash, marking one of the most consequential acquisitions in the RNA therapy space in recent years. The deal significantly...
Ground-Breaking Gene Therapy for Hunter Syndrome
Miraculous Progress for 3-Year-Old After Ground-Breaking Gene Therapy for Hunter Syndrome A three-year-old boy, Oliver Chu, has astounded doctors after becoming the first person in the world with Hunter syndrome also called MPS II to receive a pioneering gene therapy....
UK Drug Pricing Pressure Threatens Pharma Investment and Competitiveness
The row over drug pricing in the United Kingdom has escalated into a defining test for the government’s life sciences strategy. In 2025 tensions between Whitehall and major pharmaceutical companies have hardened, with a series of high-profile investment pauses and...
AstraZeneca and Sun Pharma Join Forces in India
AstraZeneca and Sun Pharma Join Forces to Expand Access to Hyperkalaemia Treatment in India In a major development for renal and cardiac care in India, AstraZeneca Pharma India and Sun Pharmaceutical Industries have announced a strategic co-marketing partnership to...
J&J Acquires Halda Therapeutics to Boost Oncology Pipeline
Johnson & Johnson has agreed to acquire Halda Therapeutics for $3.05 billion in cash, a transaction announced on 17 November 2025 and expected to close in the coming months, subject to customary regulatory approvals. Halda’s Novel RIPTAC Modality Halda...
The Future of Clinical Trials: Virtual, Decentralised, and Patient-Led
Clinical trials have long been the backbone of medical innovation, providing the evidence base for new treatments, diagnostics, and preventive measures. Yet for decades, the traditional model, site-based, paper-driven, and geographically limited, has been plagued by...
Expansion at Oxford Science Park Boosts Innovation Ecosystem
The Oxford Science Park (OSP), located on the southern edge of Oxford and owned by Magdalen College, Oxford, is entering a significant new phase of expansion aimed at strengthening the UK’s life sciences and technology infrastructure. This growth is driven by strong...
Remote Stroke Surgery Breakthrough with New Robotic System
In a landmark development for stroke treatment, medical technology company Remedy Robotics has announced what it describes as the world’s first fully remote endovascular neurointerventional procedures using its N1 robotic system. The announcement, made on 6 October...
Bacterial Movement Beyond Flagella: Surprising New Mechanisms Uncovered
Emerging Evidence of Alternative Motility For decades, scientists have believed that bacterial movement relied almost entirely on the rotation of whip-like flagella, which propel cells through liquids or across surfaces. However, new research has revealed that some...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.